IP Library Granted Patent US 7,585,527
Granted Patent B2
US 7,585,527 · App. 11/230,042 · Granted Sep 8, 2009

Composition and method for treating iron deficiency anemia

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,585,527
App. No.
11/230,042
Granted
Sep 8, 2009
Kind
B2
Abstract

A composition comprising heme iron and/or heme iron polypeptide in combination with ionic iron(s) and/or chelated iron(s). Administration of effective dosages of the present composition provides a method for treating and/or preventing iron deficiency anemia, and the physiological, biochemical, morphological, and behavioral manifestations symptomatic of same.

Claims (74)

1. A composition for treating iron deficiency anemia, consisting essentially of:

heme iron polypeptide; and,

an iron material selected from the group consisting of ionic irons, chelated irons selected from the group consisting of iron polysaccharide, iron bisglycinate and iron proteinate, and combinations thereof.

2. The composition of claim 1 , wherein said heme iron polypeptide is present in an amount between about 2 mg and about 12 mg of elemental iron.

3. The composition of claim 1 , wherein said heme iron polypeptide is present in an amount between about 6 mg and about 9 mg of elemental iron.

4. The composition of claim 1 , wherein said iron material is present in an amount between about 15 mg and about 100 mg of elemental iron.

5. The composition of claim 1 , wherein said iron material is present in an amount between about 20 mg and about 75 mg of elemental iron.

6. The composition of claim 1 , wherein said heme iron polypeptide is present in an amount of about 6 mg of elemental iron, and wherein said iron material is present in an amount of about 21 mg of elemental iron.

7. The composition of claim 1 , wherein said heme iron polypeptide is present in an amount of about 12 mg of elemental iron, and wherein said iron material is present in an amount of about 15 mg of elemental iron.

8. The composition of claim 1 , wherein said heme iron polypeptide is present in an amount of about 12 mg of elemental iron, and wherein said iron material is present in an amount of about 63 mg of elemental iron.

9. The composition of claim 1 , further comprising folic acid in an amount between about 0.1 mg and about 5 mg.

10. The composition of claim 1 , further comprising folic acid in an amount between about 0.4 mg and about 2 mg.

11. The composition of claim 1 , further comprising vitamin B12 in an amount between about 1 mcg and about 900 mcg.

12. The composition of claim 1 , further comprising vitamin B12 in an amount between about 12 mcg and about 500 mcg.

13. The composition of claim 1 , further comprising at least one of folic acid, vitamin A, vitamin B (all series), vitamin C, vitamin D, vitamin E, calcium, and magnesium.

14. A composition for treating iron deficiency anemia, consisting essentially of:

heme iron polypeptide; and,

iron polysaccharide.

15. The composition of claim 14 , wherein said heme iron polypeptide is present in an amount between about 2 mg and about 12 mg of elemental iron.

16. The composition of claim 14 , wherein said heme iron polypeptide is present in an amount between about 6 mg and about 9 mg of elemental iron.

17. The composition of claim 14 , wherein said iron polysaccharide is present in an amount between about 15 mg and about 100 mg of elemental iron.

18. The composition of claim 14 , wherein said iron polysaccharide is present in an amount between about 20 mg and about 75 mg of elemental iron.

19. The composition of claim 14 , wherein said heme iron polypeptide is present in an amount of about 6 mg of elemental iron, and wherein said iron polysaccharide is present in an amount of about 21 mg of elemental iron.

20. The composition of claim 14 , wherein said heme iron polypeptide is present in an amount of about 12 mg of elemental iron, and wherein said iron polysaccharide is present in an amount of about 15 mg of elemental iron.

21. The composition of claim 14 , wherein said heme iron polypeptide is present in an amount of about 12 mg of elemental iron, and wherein said iron polysaccharide is present in an amount of about 63 mg of elemental iron.

22. A composition for treating iron deficiency anemia, consisting essentially of:

heme iron polypeptide; and,

a chelated iron selected from the group consisting of iron polysaccharide, iron bisglycinate, iron proteinate, and combinations thereof.

23. The composition of claim 22 , wherein said heme iron polypeptide is present in an amount between about 2 mg and about 12 mg of elemental iron.

24. The composition of claim 22 , wherein said heme iron polypeptide is present in an amount between about 6 mg and about 9 mg of elemental iron.

25. The composition of claim 22 , wherein said chelated iron is present in an amount between about 15 mg and about 100 mg of elemental iron.

26. The composition of claim 22 , wherein said chelated iron is present in an amount between about 20 mg and about 75 mg of elemental iron.

27. The composition of claim 22 , wherein said heme iron polypeptide is present in an amount of about 6 mg of elemental iron, and wherein said chelated iron is present in an amount of about 21 mg of elemental iron.

28. The composition of claim 22 , wherein said heme iron polypeptide is present in an amount of about 12 mg of elemental iron, and wherein said chelated iron is present in an amount of about 15 mg of elemental iron.

29. The composition of claim 22 , wherein said heme iron polypeptide is present in an amount of about 12 mg of elemental iron, and wherein said chelated iron is present in an amount of about 63 mg of elemental iron.

30. A composition for treating iron deficiency anemia, consisting essentially of:

heme iron polypeptide;

an iron material selected from the group consisting of ionic irons, chelated irons selected from the group consisting of iron polysaccharide, iron bisglycinate and iron proteinate, and combinations thereof; and,

at least one vitamin selected from the group consisting of folic acid, vitamin B6, and vitamin B12.

31. A composition for treating iron deficiency anemia, consisting essentially of:

heme iron polypeptide;

iron polysaccharide; and,

at least one vitamin selected from the group consisting of folic acid, vitamin B6, and vitamin B12.

32. A composition for treating iron deficiency anemia, consisting essentially of:

heme iron polypeptide;

a chelated iron selected from the group consisting of iron polysaccharide, iron bisglycinate, iron proteinate, and combinations thereof; and,

at least one vitamin selected from the group consisting of folic acid, vitamin B6, and vitamin B12.

33. A composition for human consumption consisting essentially of:

a first iron ingredient, wherein said first iron ingredient is heme iron polypeptide; and,

a second iron ingredient selected from the group consisting of ionic irons, chelated irons selected from the group consisting of iron polysaccharide, iron bisglycinate and iron proteinate, and combinations thereof.

34. A composition for human consumption consisting essentially of:

heme iron polypeptide;

an iron material selected from the group consisting of ionic irons, chelated irons selected from the group consisting of iron polysaccharide, iron bisglycinate and iron proteinate, and combinations thereof and,

at least one nutrient selected from the group consisting of vitamins, minerals, and a combination thereof.

35. A composition for human consumption consisting essentially of:

heme iron polypeptide;

iron polysaccharide; and,

at least one nutrient selected from the group consisting of vitamins, minerals, and a combination thereof.

36. A composition for human consumption consisting essentially of:

heme iron polypeptide;

a chelated iron selected from the group consisting of iron polysaccharide, iron bisglycinate, iron proteinate, and combinations thereof; and,

at least one nutrient selected from the group consisting of vitamins, minerals, and a combination thereof.

37. An iron composition consisting essentially of:

heme iron polypeptide; and,

an iron material selected from the group consisting of ionic irons, chelated irons selected from the group consisting of iron polysaccharide, iron bisglycinate and iron proteinate, and combinations thereof,

wherein said iron composition is included within a dose for human administration, and wherein said dose is formulated to further include at least one vitamin and at least one mineral.

38. An iron composition consisting essentially of:

heme iron polypeptide; and,

iron polysaccharide,

wherein said iron composition is included within a dose for human administration, and wherein said dose is formulated to further include at least one vitamin and at least one mineral.

39. An iron composition consisting essentially of:

heme iron polypeptide; and,

a chelated iron selected from the group consisting of iron polysaccharide, iron bisglycinate, iron proteinate, and combinations thereof,

wherein said iron composition is included within a dose for human administration, and wherein said dose is formulated to further include at least one vitamin and at least one mineral.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2021
From: MEDA AB; ALAVEN PHARMACEUTICAL LLC
To: NURYA BRANDS, INC.
Reel/Frame 056210/0968 →
RELEASE OF SECURITY INTEREST Recorded Oct 7, 2010
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
To: ALAVEN PHARMACEUTICAL LLC
Reel/Frame 025105/0550 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2010
From: VENKATARAMAN, BALA
To: ALAVEN PHARMACEUTICAL, LLC
Reel/Frame 023892/0155 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2010
From: GUTHRIE, MICHAEL
To: COLORADO BIOLABS, INC.
Reel/Frame 023892/0173 →
THIRD AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Oct 15, 2009
From: ALAVEN PHARMACEUTICAL LLC
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
Reel/Frame 023379/0789 →
SECOND AMENDED & RESTATED PATENT SECURITY AGREEMENT Recorded Dec 16, 2008
From: ALAVEN PHARMACEUTICAL LLC
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
Reel/Frame 021993/0146 →
AMENDED & RESTATED PATENT SECURITY AGREEMENT Recorded Mar 25, 2008
From: ALAVEN PHARMACEUTICAL, LLC
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
Reel/Frame 020724/0843 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2007
From: GUTHRIE, MICHAEL
To: COLORADO BIOLABS INC.
Reel/Frame 019494/0035 →
PATENT SECURITY AGREEMENT Recorded Apr 11, 2006
From: ALAVEN PHARMACEUTICAL, LLC
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
Reel/Frame 017470/0531 →